Emergent BioSolutions Q2 revenue misses analyst expectations
Overview
Emergent Q2 revenue of $140.9 mln missed analyst expectations, exceeded Co's guidance by $21 mln
Adjusted EBITDA rose 382% to $28.5 mln, beating analyst estimates
Company raised low end/midpoint of full-year 2025 profitability guidance
Outlook
Emergent raises full-year 2025 revenue guidance to $765-$835 mln
Company revises 2025 net income forecast to $40-$65 mln
Company anticipates full-year 2025 adjusted EBITDA of $175-$200 mln
Result Drivers
NALAXONE SALES DECLINE - Revenues from NARCAN Nasal Spray fell 44% due to unfavorable price and volume mix
ANTHRAX MCM SALES TIMING - Anthrax MCM revenues decreased 70% due to timing of sales related to CYFENDUS
SMALLPOX MCM SALES INCREASE - Smallpox MCM revenues rose 127% driven by higher VIGIV CNJ-016 sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $140.90 mln | $146.40 mln (3 Analysts) |
Q2 Adjusted EPS |
| $0.16 |
|
Q2 Adjusted Net Income | Beat | $8.60 mln | -$27.60 mln (2 Analysts) |
Q2 Net Income |
| -$12 mln |
|
Q2 Adjusted EBITDA | Beat | $28.50 mln | -$10.30 mln (1 Analyst) |
Q2 Gross Margin |
| 36.0% |
|
Q2 Adjusted Gross Margin |
| 49.0% |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 54.8% above its August 5 closing price of $6.10
Press Release: ID:nGNX3qB8bL
